Evidence map›Paper›PMID 39804185›Full record

ArticleJMIR public health and surveillance2025

Updated Surveillance Metrics and History of the COVID-19 Pandemic (2020-2023) in East Asia and the Pacific Region: Longitudinal Trend Analysis.

Alexander L Lundberg, Alan G Soetikno, Scott A Wu, Egon Ozer, Sarah B Welch, Yingxuan Liu, Claudia Hawkins, Maryann Mason, Robert Murphy, Robert J Havey and 3 more

Abstract readHistorical Article
In one paragraph

Article in JMIR public health and surveillance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alexander L LundbergBuehler Center for Health Policy and Economics, Robert J Havey, MD Institute for Global Health, Northwestern University, Chicago, IL, United States.ORCID 0000-0002-9743-8441
Alan G SoetiknoFeinberg School of Medicine, Northwestern University, Chicago, IL, United States.ORCID 0000-0003-3404-1671
Scott A WuFeinberg School of Medicine, Northwestern University, Chicago, IL, United States.ORCID 0000-0003-0440-1218
Egon OzerDepartment of Medicine, Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.ORCID 0000-0002-7131-3691
Sarah B WelchBuehler Center for Health Policy and Economics, Robert J Havey, MD Institute for Global Health, Northwestern University, Chicago, IL, United States.ORCID 0000-0001-5609-3718
Yingxuan LiuBuehler Center for Health Policy and Economics, Robert J Havey, MD Institute for Global Health, Northwestern University, Chicago, IL, United States.ORCID 0000-0002-6697-0160
Claudia HawkinsDepartment of Medicine, Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.ORCID 0000-0001-7228-6317
Maryann MasonBuehler Center for Health Policy and Economics, Robert J Havey, MD Institute for Global Health, Northwestern University, Chicago, IL, United States.ORCID 0000-0001-6524-1532
Robert MurphyDepartment of Medicine, Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.ORCID 0000-0003-3936-2052
Robert J HaveyRobert J Havey, MD Institute for Global Health, Northwestern University, Chicago, IL, United States.ORCID 0000-0002-7176-058X
Charles B MossInstitute of Food and Agricultural Sciences, University of Florida, Gainesville, FL, United States.ORCID 0000-0002-1172-7112
Chad J AchenbachDepartment of Medicine, Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.ORCID 0000-0003-4847-7249
Lori Ann PostBuehler Center for Health Policy and Economics, Robert J Havey, MD Institute for Global Health, Northwestern University, Chicago, IL, United States.ORCID 0000-0002-6261-3254

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study updates the COVID-19 pandemic surveillance in East Asia and the Pacific region that we first conducted in 2020 with 2 additional years of data for the region.

objectiveFirst, we aimed to measure whether there was an expansion or contraction of the pandemic in East Asia and the Pacific region when the World Health Organization (WHO) declared the end of the COVID-19 public health emergency of international concern on May 5, 2023. Second, we used dynamic and genomic surveillance methods to describe the dynamic history of the pandemic in the region and situate the window of the WHO declaration within the broader history. Finally, we aimed to provide historical context for the course of the pandemic in East Asia and the Pacific region.

methodsIn addition to updates of traditional surveillance data and dynamic panel estimates from the original study, this study used data on sequenced SARS-CoV-2 variants from the Global Initiative on Sharing All Influenza Data to identify the appearance and duration of variants of concern. We used Nextclade nomenclature to collect clade designations from sequences and Pangolin nomenclature for lineage designations of SARS-CoV-2. Finally, we conducted a 1-sided t test to determine whether the regional weekly speed was greater than an outbreak threshold of 10. We ran the test iteratively with 6 months of data across the sample period.

resultsSeveral countries in East Asia and the Pacific region had COVID-19 transmission rates above an outbreak threshold at the point of the WHO declaration (Brunei, New Zealand, Australia, and South Korea). However, the regional transmission rate had remained below the outbreak threshold for 4 months. In the rolling 6-month window t test for regional outbreak status, the final P value ≤.10 implies a rejection of the null hypothesis (at the α=.10 level) that the region as a whole was not in an outbreak for the period from November 5, 2022, to May 5, 2023. From January 2022 onward, nearly every sequenced SARS-CoV-2 specimen in the region was identified as the Omicron variant.

conclusionsWhile COVID-19 continued to circulate in East Asia and the Pacific region, transmission rates had fallen below outbreak status by the time of the WHO declaration. Compared to other global regions, East Asia and the Pacific region had the latest outbreaks driven by the Omicron variant. COVID-19 appears to be endemic in the region, no longer reaching the threshold for a pandemic definition. However, the late outbreaks raise uncertainty about whether the pandemic was truly over in the region at the time of the WHO declaration.

Indexed as

COVID-19PandemicsPopulation SurveillanceAsia, EasternHumansLongitudinal StudiesPacific IslandsPattern Analysis, MachineSARS-CoV-2World Health Organization7-day lagaccelerationAmerican SamoaArellano-BondAustraliaBrunei DarussalamCambodiaChinaCOVID-19decelerationdynamic panelEast AsiaFederated States of MicronesiaFijiFrench Polynesiageneralized method of momentsGuamHong KongIndonesiaJapanjerkKiribatiLao People’s Democratic RepublicMacaoMalaysiaMarshall IslandsMongoliaMyanmarNauru, New CaledoniaNew ZealandNorthern Mariana IslandsPacificPalaupandemicPapua New GuineaPeople’s Democratic Republic of KoreaPhilippinespublic healthRepublic of KoreaSamoaSARS-CoV-2SingaporeSolomon IslandsspeedsurveillanceThailandTimor-LesteTongaTuvaluVanuatuVietnam

Identifiers

PMID39804185
PMCPMC11890137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.